German Breast Group, Martin-Behaim-Str. 12, Neu-Isenburg 63263, Germany.
Hematol Oncol Clin North Am. 2013 Aug;27(4):767-84, ix. doi: 10.1016/j.hoc.2013.05.006.
Lessons have recently been learned in the use of neoadjuvant chemotherapy. This article explains how diagnosis of a pathologic complete response (pCR) can avoid an unfavorable prognosis in patients with high-risk breast cancer; how the surrogacy of pCR for long-term survival remains questionable; how translational biomarker studies have not been helpful in identifying patients with a high chance of treatment benefit; assessment of the prognosis of patients without a pCR for identifying patients at high risk and which clinical trials will be available for these patients in the near future; and which patients might require less locoregional treatment.
最近在新辅助化疗的应用中吸取了一些经验教训。本文解释了病理完全缓解（pCR）的诊断如何避免高危乳腺癌患者预后不良；pCR 作为长期生存的替代指标仍然存在疑问；转化生物标志物研究在识别有治疗获益高几率的患者方面没有帮助；评估无 pCR 患者的预后，以确定高危患者，以及这些患者在不久的将来可以参加哪些临床试验；哪些患者可能需要较少的局部区域治疗。
